Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19

References

• Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:1–16. doi:10.1038/s41586-020-2012-7.
   Web of Science ®Google Scholar
• Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of Coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545–49. doi:http://dx.doi.org/10.1021/acs.orglett.1c01315.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhang Y, Wang Y, Huang Z, Songet B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30:4381–89. doi:10.1007/s00330-020-06801-0.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–69. doi:10.1038/s41586-020-2008-3.
   PubMed Web of Science ®Google Scholar
• WHO. (2021). https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
   Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel AA, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):20–128. doi:10.1056/NEJMoa2015432.
   Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1–13. doi:10.1016/j.trsl.2020.04.007.
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–18. doi:10.1016/S0140-6736(20)30937-5.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–73. doi:10.1016/j.jacc.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198–209. doi:10.1111/his.14134.
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–40. doi:10.1182/blood.2020006000.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–48. doi:10.1126/science.abb2762.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F, Shang J, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–24. doi:10.1038/s41586-020-2179-y.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–37. doi:10.1002/path.1570.
   PubMed Web of Science ®Google Scholar
• Draft landscape of COVID-19 candidate vaccines. WHO. September 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. doi:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–21.e9. doi:10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Broadbent AJ, Santos CP, Anafu A, Wimmer E, Mueller S, Subbarao K. Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. Vaccine. 2016;34(4):563–70. doi:10.1016/j.vaccine.2015.11.054.
   PubMed Web of Science ®Google Scholar
• Talon J, Salvatore M, O’-Neill RE, Nakaya Y, Zheng H, Muster T, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine unicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. Vaccine. 2016;34:563–70. doi:10.1073/pnas.070525997.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, et al. Single-Shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–88. doi:https://doi.org/10.1038/s41586-020-2607-z.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial. Lancet. 2020;395:1845–54. doi:10.1016/S0140-6736(20)31208-3.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Smith BK, Shrihari S, McCune BT, Harvey IB, Keeler SP, et al. Replication-Competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe. 2020;28(3):465–74.e4. doi:10.1016/j.chom.2020.07.018.
   PubMed Web of Science ®Google Scholar
• Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. bioRxiv. 2020 . doi:10.1101/2020.07.26.221861.
   Google Scholar
• Chen W-H, Tao X, Peng B-H, Pollet J, Strych U, Bottazzi ME, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, et al. Yeast-Expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020;38(47):7533–41. bioRxiv. doi::https://doi.org/10.1101/2020.05.15.098079.
   PubMed Web of Science ®Google Scholar
• Chen J, Miao L, Li J-M, Li Y-Y, Fang H-Q, Chen H-P. Receptor-Binding domain of SARS-CoV spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol. 2005;11:6159–64. doi:10.3748/wjg.v11.i39.6159.
   PubMed Web of Science ®Google Scholar
• Amanat F, Strohmeier S, Rathnasinghe R, Schotsaert M, Coughlan L, GarcíGarcíA-Sastre A, Krammer F. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. bioRxiv. 2020. doi:10.1101/2020.09.16.300970.
   Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383:1920–31. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Judith Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv. 2020. doi:10.1101/2020.08.17.20176651.
   Google Scholar
• Burrage DR, Koushesh S, Sofat N. Immunomodulatory drugs in the management of SARS-CoV-2. Front Immunol. 2020;11:1844. doi:10.3389/fimmu.2020.01844.
   PubMed Web of Science ®Google Scholar
• Hongchao P, Richard P, Karim QA, Marissa A, Henao-Restrepo AM, Hernández garcía C, et al. Repurposed antiviral drugs for COVID-19. medRxiv. 2020. doi:10.1101/2020.10.15.20209817.
   Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’-Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68. doi:10.1038/s41586-020-2286-9.
   PubMed Web of Science ®Google Scholar
• Brzoska J, von Eick H, Hündgen M. Commentary: why haven’t we found an effective treatment for COVID-19? Front Immunol. 2021;12:714175. doi:10.3389/fimmu.2021.714175.
   PubMed Web of Science ®Google Scholar
• Wilson P, Changrob S, Fu Y, Guthmiller J, Halfmann P, Li L, et al. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike. Research Square, University of Chicago. doi:10.21203/rs.3.rs-678247/v1.
   Google Scholar
• Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. medRxiv Preprint. doi:10.1101/2021.03.17.20200246;.
   Google Scholar
• McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–21. doi:10.1128/JVI.02012-06.
   PubMed Web of Science ®Google Scholar
• Chien-Te K. Tseng C-T, Huang C, Newman P, Wang N, Narayanan K, Watts DM, Makino S, Packard MM, Zaki SR, Teh-Sheng Chan. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81(3):1162–73. doi:10.1128/JVI.01702-06.
   PubMed Web of Science ®Google Scholar
• Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75. doi:10.1128/JVI.00737-08.
   PubMed Web of Science ®Google Scholar
• Lutz C, Maher L, Lee C, Kang W. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Hum Genomics. 2020;14:20. doi:10.1186/s40246-020-00272-6.
   PubMed Web of Science ®Google Scholar
• Akkina R. New generation of humanized mice for virus research: comparative aspects and future prospects. Virology. 2013;435:14–28. doi:10.1016/j.virol.2012.10.007.
   PubMed Web of Science ®Google Scholar
• Ernst W. Humanized mice in infectious diseases. Comp Immunol Microbiol Infect Dis. 2016;49:29–38. doi:10.1016/j.cimid.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Danner R, Chaudhari SN, Rosenberger J, Surls J, Richie TL, Brumeanu T-D, Casares S. Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One. 2011;6:e19826. doi:10.1371/journal.pone.0019826.
   PubMed Web of Science ®Google Scholar
• Majji S, Wijayalath W, Shashikumar S, Pow-Sang L, Villasante EF, Brumeanu T-D, Casares S. Differential effect of HLA class-I versus class-II transgenes on human T and B cell reconstitution and function in NRG mice. Sci Rep. 2016;6:28093. doi:10.1038/srep28093.
   PubMed Web of Science ®Google Scholar
• Wijayalath W, Majji S, Villasante EF, Brumeanu T-D, Richie TL, Casares S. Humanized HLA-DR4.RagKO.IL2RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of plasmodium falciparum malaria. Malar J. 2014;13:386. doi:10.1186/1475-2875-13-386.
   PubMed Web of Science ®Google Scholar
• Kim J, Peachman KK, Jobe O, Morrison EB, Allam A, Jagodzinski L, Casares SA, Mangala R. Tracking human immunodeficiency virus-1 infection in the humanized DRAG mouse model. Front Immunol. 2017;8:1405. eCollection 2017. doi:10.3389/fimmu.2017.01405.
   PubMed Web of Science ®Google Scholar
• Majji S, Wijayalath W, Shashikumar S, Brumeanu T-D, Casares S. Humanized DRAGA mice immunized with plasmodium falciparum sporozoites and chloroquine elicit protective pre-erythrocytic immunity. Malar J. 2018;17:114. doi:10.1186/s12936-018-2264-y.
   PubMed Web of Science ®Google Scholar
• Jiang L, Morris EK, Aguilera-Olvera R, Zhang Z, Chan TC, Shashikumar S, Chao CC, Casares SA, Ching W-M. Dissemination of orientia tsutsugamushi, a causative agent of scrub typhus, and immunological responses in the humanized DRAGA mouse. Front Immunol. 2018;9:816. eCollection 2018. doi:10.3389/fimmu.2018.00816.
   PubMed Web of Science ®Google Scholar
• Mendoza M, Gunasekera D, Pratt KP, Qi Q, Casares S, Brumeanu T-D. The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2rgc KO. NOD) establishes inducible and transmissible models for influenza type A infections. Hum Vaccin Immunother. 2020;6:2222–37. doi:10.1080/21645515.2020.1713605.
   Google Scholar
• Mendoza M, Ballesteros A, Qi Q, Pow-Sang L, Shashikumar S, Casares S, Brumeanu T-D. Generation and testing anti-influenza human mono4clonal antibodies in a new humanized mouse model (DRAGA: HLA-A2 . HLA-DR4. Rag1 KO. IL-2rgc KO. NOD). Hum Vaccin Immunother. 2018;14:345–60. doi:10.1080/21645515.2017.1403703.
   PubMed Web of Science ®Google Scholar
• Yi G, Xu X, Abraham S, Petersen S, Guo H, Ortega N, Shankar P, Manjunath N. A DNA vaccine protects human immune Cells against Zika virus infection in humanized mice. EBioMedicine. 2017;25:87–94. doi:10.1016/j.ebiom.2017.10.006.
   PubMed Web of Science ®Google Scholar
• Liu X, Zaid A, Freitas JR, McMillan NA, Mahalingam S, Taylor A. Infectious clones produce SARS-CoV-2 that causes severe pulmonary disease in infected K18-human ACE2 MicemBio. 2021;12(2):e00819–21. doi:10.1128/mBio.00819-21.
   Google Scholar
• Bi Z, Hong W, Que H, He C, Ren W, Yang J, Lu T, Chen L, Lu S, Peng X, et al. Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice. Signal Transd Target Ther. 2021;6(1):439. doi:10.1038/s41392-021-00851-6.
   PubMed Web of Science ®Google Scholar
• Pichyangkul S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Im-Erbsin R, Boonnak K, Mongkolsirichaikul D, et al. Tissue distribution of memory T and B cells in Rhesus Monkeys following influenza A infection. J Immunol. 2015;195(9):4378–86. doi:10.4049/jimmunol.1501702.
   PubMed Web of Science ®Google Scholar
• Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS. Resident memory T cells (TRM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One. 2011;6:e16245. doi:10.1371/journal.pone.0016245.
   PubMed Web of Science ®Google Scholar
• van de Ven C, Collins D, Bradley MB, Morris E, Cairo MS. The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Exp Hematol. 2007;35(12):1753–65. doi:10.1016/j.exphem.2007.08.017.
   PubMed Web of Science ®Google Scholar
• Berger MJ, Adams SD, Tigges BM, Sprague SL, Wang XJ, Collins DP, McKenna DH. Differentiation of umbilical cord blood-derived multilineage progenitor cells into respiratory epithelial cells. Cytotherapy. 2006;8(5):480–87. doi:10.1080/14653240600941549.
   PubMed Web of Science ®Google Scholar
• Mondragón-GarcíGarcíA I, Flores-Guzmán P, Mayani H. Human cord blood hematopoietic cells acquire neural features when cultured in the presence of neurogenic cytokines. Blood Cells Mol Dis. 2020;85:1–7. doi:10.1016/j.bcmd.2020.102485.
   Web of Science ®Google Scholar
• Almeida-Porada G, Porada CD, Chamberlain J, Torabi A, Zanjani ED. Formation of human hepatocytes by human hematopoietic stem cells in sheep. Blood. 2004;104(8):2582–90. doi:10.1182/blood-2004-01-0259.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Yoshida S, Nakamura K, Nagatoshi Y, Kanemaru T, Shimoda K, Shimoda S, Miyamoto T, Okamura J et al. Human cord blood- and bone marrow-derived CD34_cells regenerate gastrointestinal epithelial cells. Faseb J. 2004;18:1958–60. doi:10.1096/fj.04-2396fje.
   PubMed Web of Science ®Google Scholar
• Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6(11):1229–34. doi:10.1038/81326.
   PubMed Web of Science ®Google Scholar
• De Paepe ME, Mao Q, Ghanta S, Hovanesian V, James F. Padbury JF. Alveolar epithelial cell therapy with human cord blood–Derived hematopoietic progenitor cells. Am J Pathol. 2011;178(3):1329–39. doi:10.1016/j.ajpath.2010.11.062.
   PubMed Web of Science ®Google Scholar
• Jin JM, Bai P, He W, Wu F, Liu XF, Han D-M, Liu S, Yang J-K. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi:10.3389/fpubh.2020.00152.
   PubMed Web of Science ®Google Scholar
• Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–47. doi:10.1038/s41577-020-0348-8.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based differences in susceptibility to severe acute respiratory syndrome Coronavirus infection. J Immunol. 2017;198(10):4046–53. doi:10.4049/jimmunol.1601896.
   PubMed Web of Science ®Google Scholar
• Wehbe Z, Hammoud SH, Yassine HM, Fardoun M, Ahmed F. El-Yazbi AF, Eid AH. Molecular and biological mechanisms underlying gender differences in COVID-19 severity and mortality. Front Immunol. 2021;12:1–14. doi:10.3389/fimmu.2021.659339.
   Web of Science ®Google Scholar
• Froldi G, Dorigo P. Endothelial dysfunction in coronavirus disease COVID-19: gender and age influences. Med Hypotheses. 2020;144:110015. doi:10.1016/j.mehy.2020.110015.
   PubMed Web of Science ®Google Scholar
• Shabbir S, Hafeez A, Rafiq MA, Khan MJ. Estrogen shields women from COVID-19 complications by reducing ER stress. Med Hypotheses. 2020;143:110148. doi:10.1016/j.mehy.2020.110148.
   PubMed Web of Science ®Google Scholar
• Garg R, Agrawal P, Gautam A, Pursnani N, Agarwal M, Agarwal A, Parihar A, Pandey A. COVID-19 outcomes in postmenopausal and perimenopausal females: is estrogen hormone attributing to gender differences? J Midlife Health. 2020;11(4):250–56. doi:10.4103/jmh.jmh_287_20.
   PubMedGoogle Scholar
• Kim JY, Ko J-H, Kim Y, Kim Y-J, Kim J-M, Chung Y-S, Kim HM, Han MG, Kim SY, Chin BS. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. 2020;35(7):e86. doi:10.3346/jkms.2020.35.e86.
   PubMed Web of Science ®Google Scholar
• Regan J, James P, Flynn JP, Rosenthal A, Jordan H, Li Y, Chishti R, Giguel F, Corry H, Coxen K, et al. Viral load kinetics of SARS-CoV-2 in hospitalized individuals with COVID-19. Open Forum Infect Dis. 2021;8(8):ofab153. eCollection 2021 Aug. doi:10.1093/ofid/ofab153.
   PubMed Web of Science ®Google Scholar
• Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 1:e13–e22. doi:10.1016/S2666-5247(20)30172-5.
   PubMedGoogle Scholar
• Zhou B, Zhao W, Feng R, Zhang X, Li X, Zhou Y, Peng L, Li Y, Zhang J, Luo J, et al. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review. Pathog Dis. 2020;78(3):ftaa026. doi:10.1093/femspd/ftaa026.
   PubMed Web of Science ®Google Scholar
• Sauter JL, Baine MK, Butnor KJ, Buonocore DJ, Chang JC, Jungbluth AA, Szabolcs MJ, Morjaria S, Mount SL, Rekhtman N, et al. Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology. 2020;77(6):915–25. doi:10.1111/his.14201.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–22. doi:10.1016/S2213-2600(20)30076-X.
   PubMed Web of Science ®Google Scholar
• de Bree GJ, van Leeuwen EMM, Out TA, Jansen HM, Jonkers RE, van Lier REW. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med. 2005;202(10):1433–42. doi:10.1084/jem.20051365.
   PubMed Web of Science ®Google Scholar
• Slütter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity. 2013;39(5):939–48. doi:10.1016/j.immuni.2013.09.013.
   PubMed Web of Science ®Google Scholar
• Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, Fox JM, Chen RE, Alsoussi WA, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744–53 e4. doi:10.1016/j.cell.2020.06.011.
   PubMed Web of Science ®Google Scholar
• Cohen J. Antibodies may curb pandemic before vaccines. Science. 2020;369(6505):752–53. doi:10.1126/science.369.6505.752.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–49. doi:10.1038/s41586-020-2548-6.
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–68. doi:10.1016/j.cell.2020.08.017.
   PubMed Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Hui Yen Chng HY, Lin M, Tan N, Linster M, et al. SARS-CoV-2-Specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–62. doi:10.1038/s41586-020-2550-z.
   PubMed Web of Science ®Google Scholar
• Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis. 2014;17(3):499–509. doi:10.1007/s10456-014-9428-3.
   PubMed Web of Science ®Google Scholar
• Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Hindawi Pulm Med. 2020;2020:1–10. doi:10.1155/2020/6175964.
   Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114(3):438–46. doi:10.1172/JCI200420997.
   PubMed Web of Science ®Google Scholar
• Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome Coronavirus infection. J Virol. 2017;91(12):1–17. doi:10.1128/JVI.00182-17.
   Web of Science ®Google Scholar
• Sefik E, Israelow B, Mirza H, Zhao J, Qu R, Kaffe E, Song E, Halene S, Mefrre E, Kluger Y, et al. A humanized mouse model for chronic COVID-19. Nat Biotechnol. 2021. doi:10.1038/s41587-021-01155-4.
   PubMed Web of Science ®Google Scholar